PLx Pharma Inc. (PLXP)
PLXPPrice: $0.09
Fair Value: 🔒
🔒score
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associ... more
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the Unit... more
Description
Shares
| Market Cap | $2.53M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Natasha Giordano |
| IPO Date | 2014-03-13 | CAGR | — |
| Employees | 16 | Website | plxpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -341.62% | Total Yield | -341.62% |
PLXP chart loading...
Fundamentals
Technicals
| Enterprise Value | $-7.24M | P/E Ratio | -0.22 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.31 | P/B Ratio | 0.04 |
| P/CF Ratio | -0.06 | P/FCF Ratio | -0.08 |
| EPS | $-0.39 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -31.32% | Gross Margin | 0.41% |
| Operating Margin | -4.97% | Profit Margin | -6.27% |
| ROE | -1.66% | ROA | -0.67% |
| ROCE | -0.63% | Current Ratio | 6.19 |
| Quick Ratio | 5.98 | Cash Ratio | 5.84 |
| Debt/Equity | — | Interest Coverage | -40790 |
| Altman Z Score | -10.32 | Piotroski Score | 1 |